Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy

Phase 2/3 Unknown 64 enrolled Jiangsu Province Hospital of Traditional Chinese Medicine

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to estimate the usefulness and safety of HD6610 granule for oxaliplatin-induced peripheral neuropathy. The investigators examined the efficacy and safety of the treatment algorithm for 64 patients with colorectal cancer by evaluating the side effects and degree of improvement of subjective symptoms.

Timeline

Start: 2015-08
Primary completion: 2017-10
Completion: 2017-10

Publications

Background Balayssac D, Ferrier J, Pereira B, Gillet B, Petorin C, Vein J, Libert F, Eschalier A, Pezet D. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open. 2015 Apr 1;5(4):e007479. doi: 10.1136/bmjopen-2014-007479.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HD6610 Granule	Unknown	—	—
Background	Capecitabine	Small molecule	1000 mg/m2	—
Background	Leucovorin	Small molecule	400 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous

Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy

Summary

Timeline

Publications

Drugs

Indications